MorphoSys AG (MOR)

Aug 5, 2024 - MOR was delisted (reason: voluntary delisting)
18.96
+0.45 (2.43%)
Inactive · Last trade price on Aug 2, 2024
144.65%
Market Cap 2.86B
Revenue (ttm) 264.75M
Net Income (ttm) -210.82M
Shares Out 150.65M
EPS (ttm) -1.52
PE Ratio n/a
Forward PE 322.58
Dividend n/a
Ex-Dividend Date n/a
Volume 19,165
Open 18.38
Previous Close 18.51
Day's Range 18.38 - 19.15
52-Week Range 4.19 - 19.50
Beta 0.67
Analysts Hold
Price Target 12.13 (-36.02%)
Earnings Date Aug 29, 2024

About MOR

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company’s product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 9, 1999
Employees 524
Stock Exchange NASDAQ
Ticker Symbol MOR
Full Company Profile

Financial Performance

In 2023, MorphoSys AG's revenue was 238.28 million, a decrease of -14.37% compared to the previous year's 278.27 million. Losses were -189.73 million, 25.6% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for MOR stock is "Hold." The 12-month stock price forecast is $12.13, which is a decrease of -36.02% from the latest price.

Price Target
$12.13
(-36.02% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Novartis: launch of Morphosys drug by could be 2027 or later

Novartis' CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safet...

Other symbols: NVS
21 days ago - Reuters

Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting

MUNICH, GERMANY / ACCESSWIRE / August 27, 2024 / MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company's Management Board and Supervisory Board at its 202...

3 months ago - Accesswire

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American...

5 months ago - Business Wire

MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority Shareholders

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following ...

6 months ago - Business Wire

Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG's Minority Shareholders

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to me...

6 months ago - Accesswire

Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash

Basel, 16 May 2024 – Today, Novartis BidCo AG, an (indirect) wholly owned subsidiary of Novartis AG, announced the result of its voluntary public takeover offer (the “Offer”) for the shares of MorphoS...

Other symbols: NVS
7 months ago - GlobeNewsWire

MorphoSys: Hold Rating Until The Novartis Deal Closes

MorphoSys acquired by Novartis for EUR 2.7 billion, showcasing a significant premium over pre-announcement share price. The deal is expected to go through smoothly based on regulatory approvals receiv...

8 months ago - Seeking Alpha

MorphoSys AG Reports First Quarter 2024 Financial Results

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024. “The proposed acquisition by Novartis is advancing steadily, and we contin...

8 months ago - Business Wire

Morphosys says Novartis takeover progressing as planned for H1 2024

Morphosys said its takeover by Novartis was still expected to be closed in the first half of this year, in a statement responding to a possible safety risk reported by specialist news website STAT New...

Other symbols: NVS
8 months ago - Reuters

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR...

8 months ago - Accesswire

MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during t...

8 months ago - Accesswire

Novartis begins tender offer for MorphoSys

Novartis said on Thursday that its tender offer for MorphoSys has begun, with an offer price of 68 euros ($73.08) per share in cash, corresponding to a premium of 142% on the volume-weighted average p...

Other symbols: NVS
8 months ago - Reuters

Novartis tender offer for MorphoSys AG commences

Basel, April 11, 2024 – Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG ...

Other symbols: NVS
8 months ago - GlobeNewsWire

MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvement...

9 months ago - Accesswire

MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript

MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript

9 months ago - Seeking Alpha

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023. “In 2023, we demonstrated the potential for pelabresib to ...

9 months ago - Business Wire

Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm ...

9 months ago - Accesswire

Novartis to acquire German Biotech MorphoSys for $2.9B, Expanding Cancer Drug Pipeline

Novartis (NVS) has struck a deal to buy German biotech firm MorphoSys (MOR), a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), as the Swiss drugmaker expands its roster of cancer...

Other symbols: NVS
11 months ago - Investopedia

Novartis to bolster its oncology portfolio with acquisition of MorphoSys

Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion).

Other symbols: NVS
11 months ago - Market Watch

Novartis acquiring cancer drug developer Morphosys for €2.7 billion

CNBC's Steve Kovach joins 'Closing Bell Overtime' with breaking news out of the pharmaceutical space.

Other symbols: NVS
11 months ago - CNBC Television

MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

Tafasitamab sold to Incyte Novartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cash Shareholders benefit from attractive premium of 94 perc...

11 months ago - Accesswire

Novartis acquires cancer drug developer MorphoSys for $2.9 bln

Drugmaker Novartis AG said on Monday is has acquired MorphoSys AG , a developer of cancer treatments, for 2.7 billion euros. ($2.90 billion)

Other symbols: NVS
11 months ago - Reuters

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash

Basel, February 05, 2024 – Novartis today announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (FSE: MOR; NASDAQ: MOR), a Germany-based, gl...

Other symbols: NVS
11 months ago - GlobeNewsWire

Exclusive: Novartis in the lead to acquire cancer drug developer MorphoSys-sources

Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG , a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar with the matter ...

Other symbols: NVS
11 months ago - Reuters

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability

Preliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (€ 85.0 million) and preliminary gross margin for Monjuvi U.S. net product sales of 69% Anticipated 2024 Monjuvi U.S. net product sa...

11 months ago - Accesswire